View in EDS

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.

Saved in:
Bibliographic Details
Title: A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Authors: Lu G; Portola Pharmaceuticals, Inc., South San Francisco, CA., Conley PB; Portola Pharmaceuticals, Inc., South San Francisco, CA., Leeds JM; Portola Pharmaceuticals, Inc., South San Francisco, CA., Karbarz MJ; Portola Pharmaceuticals, Inc., South San Francisco, CA., Levy GG; Portola Pharmaceuticals, Inc., South San Francisco, CA., Mathur VS; Mathur Consulting, San Francisco, CA; and., Castillo J; Portola Pharmaceuticals, Inc., South San Francisco, CA., Crowther M; Department of Medicine, McMaster University, Hamilton, ON, Canada., Curnutte JT; Portola Pharmaceuticals, Inc., South San Francisco, CA.
Source: Blood advances [Blood Adv] 2020 Feb 25; Vol. 4 (4), pp. 728-739.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32092140
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lu+G%22">Lu G</searchLink>; Portola Pharmaceuticals, Inc., South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Conley+PB%22">Conley PB</searchLink>; Portola Pharmaceuticals, Inc., South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Leeds+JM%22">Leeds JM</searchLink>; Portola Pharmaceuticals, Inc., South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Karbarz+MJ%22">Karbarz MJ</searchLink>; Portola Pharmaceuticals, Inc., South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Levy+GG%22">Levy GG</searchLink>; Portola Pharmaceuticals, Inc., South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Mathur+VS%22">Mathur VS</searchLink>; Mathur Consulting, San Francisco, CA; and.<br /><searchLink fieldCode="AU" term="%22Castillo+J%22">Castillo J</searchLink>; Portola Pharmaceuticals, Inc., South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Crowther+M%22">Crowther M</searchLink>; Department of Medicine, McMaster University, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Curnutte+JT%22">Curnutte JT</searchLink>; Portola Pharmaceuticals, Inc., South San Francisco, CA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2020 Feb 25; Vol. 4 (4), pp. 728-739.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32092140
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2019000885
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 728
    Titles:
      – TitleFull: A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lu G
      – PersonEntity:
          Name:
            NameFull: Conley PB
      – PersonEntity:
          Name:
            NameFull: Leeds JM
      – PersonEntity:
          Name:
            NameFull: Karbarz MJ
      – PersonEntity:
          Name:
            NameFull: Levy GG
      – PersonEntity:
          Name:
            NameFull: Mathur VS
      – PersonEntity:
          Name:
            NameFull: Castillo J
      – PersonEntity:
          Name:
            NameFull: Crowther M
      – PersonEntity:
          Name:
            NameFull: Curnutte JT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 02
              Text: 2020 Feb 25
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1